We have located links that may give you full text access.
CLINICAL TRIAL
CONTROLLED CLINICAL TRIAL
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Down syndrome and Alzheimer disease: response to donepezil.
Archives of Neurology 2002 July
BACKGROUND: Individuals with Down syndrome who develop Alzheimer disease may show an improvement in cognitive functioning after treatment with acetylcholinesterase inhibitors.
OBJECTIVE: To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment.
DESIGN: A nonrandomized controlled trial using donepezil in a pilot study format.
SETTING: Academic medical center.
PATIENTS: Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects.
INTERVENTION: Oral administration of donepezil for a 5-month period.
PRIMARY OUTCOME MEASURE: The Down Syndrome Dementia Scale.
RESULTS: Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03).
CONCLUSIONS: Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
OBJECTIVE: To determine whether individuals with Down syndrome and Alzheimer disease will show improvement after institution of donepezil treatment.
DESIGN: A nonrandomized controlled trial using donepezil in a pilot study format.
SETTING: Academic medical center.
PATIENTS: Convenience sample of 6 treated patients with Down syndrome and 9 closely matched historical control subjects.
INTERVENTION: Oral administration of donepezil for a 5-month period.
PRIMARY OUTCOME MEASURE: The Down Syndrome Dementia Scale.
RESULTS: Significant improvement in dementia scores for the treated group during a 3- to 5-month period (P =.03).
CONCLUSIONS: Acetylcholinesterase inhibitors may be helpful in reversing the symptoms of dementia during early and middle stages of cognitive decline. These findings support the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app